Vascular Biogenics Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.481 million compared to USD 0.199 million a year ago. Net loss was USD 9.17 million compared to USD 6.5 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.09 a year ago.
For the nine months, sales was USD 0.658 million compared to USD 0.572 million a year ago. Net loss was USD 29.03 million compared to USD 20.81 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.33 a year ago.